Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.

Chapman RS, Whetton AD, Chresta CM, Dive C.

Mol Pharmacol. 1995 Aug;48(2):334-43.

PMID:
7651367
2.
4.

Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.

Evans CA, Owen-Lynch PJ, Whetton AD, Dive C.

Cancer Res. 1993 Apr 15;53(8):1735-8.

5.

The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase.

Chapman RS, Whetton AD, Dive C.

Cancer Res. 1994 Oct 1;54(19):5131-7.

6.
7.

Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCbetaII.

Xenaki D, Pierce A, Underhill-Day N, Whetton AD, Owen-Lynch PJ.

Cell Signal. 2004 Feb;16(2):145-56.

PMID:
14636885
8.

Role of the C-terminal actin binding domain in BCR/ABL-mediated survival and drug resistance.

Underhill-Day N, Pierce A, Thompson SE, Xenaki D, Whetton AD, Owen-Lynch PJ.

Br J Haematol. 2006 Mar;132(6):774-83.

PMID:
16487179
9.

Abl protein kinase abrogates the response of multipotent haemopoietic cells to the growth inhibitor macrophage inflammatory protein-1 alpha.

Wark G, Heyworth CM, Spooncer E, Czaplewski L, Francis JM, Dexter TM, Whetton AD.

Oncogene. 1998 Mar 12;16(10):1319-24.

10.
11.

Role of acid/base homeostasis in the suppression of apoptosis in haemopoietic cells by v-Abl protein tyrosine kinase.

Chen Q, Benson RS, Whetton AD, Brant SR, Donowitz M, Montrose MH, Dive C, Watson AJ.

J Cell Sci. 1997 Feb;110 ( Pt 3):379-87.

12.

Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation.

Pierce A, Spooncer E, Wooley S, Dive C, Francis JM, Miyan J, Owen-Lynch PJ, Dexter TM, Whetton AD.

Oncogene. 2000 Nov 16;19(48):5487-97.

14.

v-Abl protein-tyrosine kinase up-regulates p21WAF-1 in cell cycle arrested and proliferating myeloid cells.

Khanna SJ, Brown R, Whetton AD, Ball KL, Dive C.

J Biol Chem. 2001 Apr 6;276(14):11143-50. Epub 2000 Nov 29.

15.
16.

Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.

Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, Toyama K.

Exp Hematol. 1995 Oct;23(11):1153-9.

PMID:
7556524
17.
18.

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, Palumbo GA, Di Raimondo F.

Eur J Haematol. 2011 Mar;86(3):216-25. doi: 10.1111/j.1600-0609.2010.01570.x. Epub 2011 Feb 8.

PMID:
21198861

Supplemental Content

Support Center